{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T18:41:27Z","timestamp":1770144087517,"version":"3.49.0"},"reference-count":34,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,5,9]],"date-time":"2024-05-09T00:00:00Z","timestamp":1715212800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Heliyon"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1016\/j.heliyon.2024.e31054","type":"journal-article","created":{"date-parts":[[2024,5,13]],"date-time":"2024-05-13T22:02:23Z","timestamp":1715637743000},"page":"e31054","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Research hotspots and trends in biological agents for psoriasis: Visualization and bibliometric analysis"],"prefix":"10.1016","volume":"10","author":[{"given":"Si-Yu","family":"Long","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lin","family":"Shang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Siqi","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huijuan","family":"Shi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan-Ling","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.heliyon.2024.e31054_bib1","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1056\/NEJMra0804595","article-title":"Psoriasis","volume":"361","author":"Nestle","year":"2009","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.heliyon.2024.e31054_bib2","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1038\/jid.2012.339","article-title":"Global epidemiology of psoriasis: a systematic review of incidence and prevalence","volume":"133","author":"Parisi","year":"2013","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.heliyon.2024.e31054_bib3","article-title":"National, regional, and worldwide epidemiology of psoriasis: systematic analysis and modelling study","volume":"369","author":"Parisi","year":"2020","journal-title":"BMJ"},{"issue":"5","key":"10.1016\/j.heliyon.2024.e31054_bib4","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1016\/j.jaad.2008.02.039","article-title":"Guidelines of care for the management of psoriasis and psoriatic arthritis: section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics","volume":"58","author":"Menter","year":"2008","journal-title":"J. Am. Acad. Dermatol."},{"issue":"6","key":"10.1016\/j.heliyon.2024.e31054_bib5","doi-asserted-by":"crossref","DOI":"10.2196\/32728","article-title":"Research trends in immune checkpoint blockade for melanoma: visualization and bibliometric analysis","volume":"24","author":"Xu","year":"2022","journal-title":"J. Med. Internet Res."},{"issue":"3","key":"10.1016\/j.heliyon.2024.e31054_bib6","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1002\/asi.21694","article-title":"Predictive effects of structural variation on citation counts","volume":"63","author":"Chen","year":"2012","journal-title":"J. Am. Soc. Inf. Sci. Technol."},{"issue":"9227","key":"10.1016\/j.heliyon.2024.e31054_bib7","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/S0140-6736(00)02530-7","article-title":"Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial","volume":"356","author":"Mease","year":"2000","journal-title":"Lancet"},{"issue":"9625","key":"10.1016\/j.heliyon.2024.e31054_bib8","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1016\/S0140-6736(08)60725-4","article-title":"Efficacy and safety of ustekinumab, a human interleukin-12\/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)","volume":"371","author":"Leonardi","year":"2008","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.heliyon.2024.e31054_bib9","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1056\/NEJMoa1314258","article-title":"Secukinumab in plaque psoriasis--results of two phase 3 trials","volume":"371","author":"Langley","year":"2014","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.heliyon.2024.e31054_bib10","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.jaad.2016.11.041","volume":"76","author":"Blauvelt","year":"2017","journal-title":"J. Am. Acad. Dermatol."},{"issue":"5","key":"10.1016\/j.heliyon.2024.e31054_bib11","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1111\/j.1365-2133.2011.10615.x","article-title":"Efficacy and safety of infliximab vs. methotrexate in patients with moderate-to-severe plaque psoriasis: results of an open-label, active-controlled, randomized trial (RESTORE1)","volume":"165","author":"Barker","year":"2011","journal-title":"Br. J. Dermatol."},{"issue":"2","key":"10.1016\/j.heliyon.2024.e31054_bib12","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.bcp.2014.08.027","article-title":"Therapeutic targeting of the inflammome","volume":"92","author":"Wright","year":"2014","journal-title":"Biochem. Pharmacol."},{"issue":"2","key":"10.1016\/j.heliyon.2024.e31054_bib13","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1056\/NEJMoa0810652","article-title":"Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis","volume":"362","author":"Griffiths","year":"2010","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.heliyon.2024.e31054_bib14","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.jaad.2015.05.013","article-title":"Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial","volume":"73","author":"Tha\u00e7i","year":"2015","journal-title":"J. Am. Acad. Dermatol."},{"issue":"10201","key":"10.1016\/j.heliyon.2024.e31054_bib15","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/S0140-6736(19)31773-8","article-title":"Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial","volume":"394","author":"Reich","year":"2019","journal-title":"Lancet"},{"issue":"21","key":"10.1016\/j.heliyon.2024.e31054_bib16","doi-asserted-by":"crossref","first-page":"2014","DOI":"10.1056\/NEJMoa030409","article-title":"Etanercept as monotherapy in patients with psoriasis","volume":"349","author":"Leonardi","year":"2003","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.heliyon.2024.e31054_bib17","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.jaad.2007.09.010","article-title":"Adalimumab therapy for moderate to severe psoriasis: a randomized, controlled phase III trial","volume":"58","author":"Menter","year":"2008","journal-title":"J. Am. Acad. Dermatol."},{"issue":"9993","key":"10.1016\/j.heliyon.2024.e31054_bib18","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/S0140-6736(15)60125-8","article-title":"Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials","volume":"386","author":"Griffiths","year":"2015","journal-title":"Lancet"},{"issue":"14","key":"10.1016\/j.heliyon.2024.e31054_bib19","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1056\/NEJMoa1503824","article-title":"Phase 3 studies comparing brodalumab with ustekinumab in psoriasis","volume":"373","author":"Lebwohl","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.heliyon.2024.e31054_bib20","article-title":"Pharmacovigilance bibliometrics: visualizing thematic development in the category of pharmacology and pharmacy in Web of science","volume":"12","author":"Wang","year":"2021","journal-title":"Front. Pharmacol."},{"issue":"4","key":"10.1016\/j.heliyon.2024.e31054_bib21","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1111\/bjd.21617","article-title":"Maintenance of response in moderate-to-severe psoriasis after withdrawal of the interleukin (IL)-17A and IL-17F nanobody sonelokimab: is there a role for IL-17F in disease reoccurrence?","volume":"187","author":"Reich","year":"2022","journal-title":"Br. J. Dermatol."},{"issue":"5","key":"10.1016\/j.heliyon.2024.e31054_bib22","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1111\/bjd.20880","article-title":"HSP90 inhibitor RGRN-305 for oral treatment of plaque-type psoriasis: efficacy, safety and biomarker results in an open-label proof-of-concept study","volume":"186","author":"Bregnh\u00f8j","year":"2022","journal-title":"Br. J. Dermatol."},{"issue":"6","key":"10.1016\/j.heliyon.2024.e31054_bib23","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1111\/bjd.21743","article-title":"Efficacy and safety of mirikizumab in psoriasis: results from a 52-week, double-blind, placebo-controlled, randomized withdrawal, phase III trial (OASIS-1)","volume":"187","author":"Blauvelt","year":"2022","journal-title":"Br. J. Dermatol."},{"issue":"3","key":"10.1016\/j.heliyon.2024.e31054_bib24","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1111\/bjd.21233","article-title":"Secukinumab demonstrates high and sustained efficacy in nail psoriasis: post hoc analysis from phase III trials in patients with psoriatic arthritis","volume":"187","author":"Reich","year":"2022","journal-title":"Br. J. Dermatol."},{"issue":"5","key":"10.1016\/j.heliyon.2024.e31054_bib25","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1111\/bjd.20963","article-title":"The biological basis of disease recurrence in psoriasis: a historical perspective and current models","volume":"186","author":"Puig","year":"2022","journal-title":"Br. J. Dermatol."},{"issue":"6","key":"10.1016\/j.heliyon.2024.e31054_bib26","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1111\/bjd.20971","article-title":"Secukinumab dosing every 2 weeks demonstrated superior efficacy compared with dosing every 4 weeks in patients with psoriasis weighing 90 kg or more: results of a randomized controlled trial","volume":"186","author":"Augustin","year":"2022","journal-title":"Br. J. Dermatol."},{"issue":"6","key":"10.1016\/j.heliyon.2024.e31054_bib27","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1111\/bjd.20980","article-title":"Paradoxical psoriasis after exposure to tumour necrosis factor inhibitors in children: a retrospective cohort study","volume":"186","author":"Kodama","year":"2022","journal-title":"Br. J. Dermatol."},{"issue":"4","key":"10.1016\/j.heliyon.2024.e31054_bib28","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1111\/bjd.20885","article-title":"Treatment satisfaction, safety and effectiveness of adding methotrexate to adalimumab in patients with psoriasis responding suboptimally to adalimumab in a real-world setting","volume":"186","author":"Papp","year":"2022","journal-title":"Br. J. Dermatol."},{"issue":"3","key":"10.1016\/j.heliyon.2024.e31054_bib29","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1111\/bjd.20947","article-title":"Safety in numbers: risankizumab for moderate-to-severe psoriasis","volume":"186","author":"Mirali","year":"2022","journal-title":"Br. J. Dermatol."},{"issue":"9271","key":"10.1016\/j.heliyon.2024.e31054_bib30","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1016\/S0140-6736(00)04954-0","article-title":"Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial","volume":"357","author":"Chaudhari","year":"2001","journal-title":"Lancet"},{"issue":"9494","key":"10.1016\/j.heliyon.2024.e31054_bib31","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1016\/S0140-6736(05)67566-6","article-title":"Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial","volume":"366","author":"Reich","year":"2005","journal-title":"Lancet"},{"issue":"9625","key":"10.1016\/j.heliyon.2024.e31054_bib32","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1016\/S0140-6736(08)60726-6","article-title":"Efficacy and safety of ustekinumab, a human interleukin-12\/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)","volume":"371","author":"Papp","year":"2008","journal-title":"Lancet"},{"issue":"13","key":"10.1016\/j.heliyon.2024.e31054_bib33","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1056\/NEJMoa1109997","article-title":"Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis","volume":"366","author":"Leonardi","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.heliyon.2024.e31054_bib34","volume":"152","author":"Papp","year":"2005"}],"container-title":["Heliyon"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405844024070853?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405844024070853?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T23:46:40Z","timestamp":1761781600000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405844024070853"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":34,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["S2405844024070853"],"URL":"https:\/\/doi.org\/10.1016\/j.heliyon.2024.e31054","relation":{},"ISSN":["2405-8440"],"issn-type":[{"value":"2405-8440","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Research hotspots and trends in biological agents for psoriasis: Visualization and bibliometric analysis","name":"articletitle","label":"Article Title"},{"value":"Heliyon","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.heliyon.2024.e31054","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"e31054"}}